Effect of Medications for Gastric Acid-Related Symptoms on Total Motile Sperm Count and Concentration: A Case-Control Study in Men of Subfertile Couples from the Netherlands.

Abstract:

INTRODUCTION:Gastric acid-related symptoms are highly prevalent in the general population (21-40%), and more than 11% of individuals use medication for the treatment of these symptoms. The uptake of micronutrients is dependent on the gastrointestinal potential of hydrogen (pH). OBJECTIVE:We hypothesized that medication affecting gastrointestinal pH reduces the availability of B vitamins, thereby deranging one-carbon metabolism and detrimentally affecting spermatogenesis. METHODS:This explorative nested case-control study in men of subfertile couples investigated associations between medication used for gastric acid-related symptoms and semen parameters. We included 40 men using medication for gastric acid-related symptoms and 843 men not using medication. Semen analyses were performed between 70 days before and 21 days after the visit. RESULTS:The use of medication was associated with a twofold higher risk of a low total motile sperm count [TMSC <1 × 106, odds ratio (OR) 2.090, p = 0.049] and negatively with sperm concentration (β -0.320, p = 0.028). Red blood cell folate was positively associated with TMSC (β 0.257, p = 0.026), sperm count (β 1.679, p = 0.013) and ejaculate volume (β 0.120, p = 0.023), and total homocysteine (tHcy) was negatively associated with sperm count (β -0.077, p = 0.021). CONCLUSION:Here we delineate associations between the use of medication for gastric acid-related symptoms and poor semen quality in men of subfertile couples. The use of medication for gastric acid-related symptoms is associated with a twofold higher risk of a low TMSC and a decreased sperm concentration. Although these findings warrant further research on causality, the associations between folate, tHcy and semen quality emphasize the importance of preconception counselling in male subfertility.

journal_name

Drug Saf

journal_title

Drug safety

authors

Huijgen NA,Goijen HJ,Twigt JM,Mulders AG,Lindemans J,Dohle GR,Laven JS,Steegers-Theunissen RP

doi

10.1007/s40264-016-0488-8

subject

Has Abstract

pub_date

2017-03-01 00:00:00

pages

241-248

issue

3

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-016-0488-8

journal_volume

40

pub_type

杂志文章
  • Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

    abstract::After 2002, an association between stroke and antipsychotic use was reported in clinical trials and large database studies. This review considers previous quantitative reviews, newly published clinical trials, and recent observational cohort and case-control studies, and focuses on the clinical significance of the ris...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11319120-000000000-00000

    authors: Sacchetti E,Turrina C,Valsecchi P

    更新日期:2010-04-01 00:00:00

  • A risk-benefit assessment of anti-obesity drugs.

    abstract::This review evaluates the benefits and potential health risks of the currently used drugs that are approved for the pharmacological treatment of obesity. Analysis of several long term clinical trials indicates that all of these drugs are efficient in reducing excess bodyweight, and that the majority of them allow the ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920020-00003

    authors: Kolanowski J

    更新日期:1999-02-01 00:00:00

  • Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

    abstract::Osteoporosis is a major public health problem occurring primarily among the postmenopausal population. Osteoporosis is a preventable disease, but despite several advances in its prevention, treatment of the established disease to date remains a major challenge to be managed by primary care physicians. Stabilisation of...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411030-00004

    authors: Gennari C,Nuti R,Agnusdei D,Camporeale A,Martini G

    更新日期:1994-09-01 00:00:00

  • Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.

    abstract:BACKGROUND:Atypical antipsychotics have been associated with metabolic abnormalities including impaired glucose metabolism, exacerbation of existing diabetes mellitus and new-onset type 2 diabetes. Not all atypical antipsychotic agents appear to have the same propensity to cause these complications. OBJECTIVE:To asses...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730070-00004

    authors: Ramaswamy K,Kozma CM,Nasrallah H

    更新日期:2007-01-01 00:00:00

  • Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

    abstract::NSAIDs are widely used to treat pain and inflammation in osteoarthritis. Their use in this indication is generally intermittent and fluctuates with the intensity of the disease. Nonetheless, success of the therapy is frequently limited by injury to the gastrointestinal mucosa and complications such as bleeding, ulcera...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427030-00003

    authors: Schmidt H,Woodcock BG,Geisslinger G

    更新日期:2004-01-01 00:00:00

  • Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

    abstract:BACKGROUND:While cases of amyotrophic lateral sclerosis (ALS) or ALS-like conditions have arisen in apparent association with HMG-CoA reductase inhibitors ('statins') and/or other lipid-lowering drugs (collectively termed 'statins' in this paper for brevity), additional information is needed to understand whether the c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932080-00004

    authors: Golomb BA,Kwon EK,Koperski S,Evans MA

    更新日期:2009-01-01 00:00:00

  • All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

    abstract:INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-00786-y

    authors: Jeong S,Tchoe HJ,Li J,Shin JY

    更新日期:2019-06-01 00:00:00

  • Evaluation of Use of Technologies to Facilitate Medical Chart Review.

    abstract:INTRODUCTION:While medical chart review remains the gold standard to validate health conditions or events identified in administrative claims and electronic health record databases, it is time consuming, expensive and can involve subjective decisions. AIM:The aim of this study was to describe the landscape of technolo...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00838-x

    authors: Straub L,Gagne JJ,Maro JC,Nguyen MD,Beaulieu N,Brown JS,Kennedy A,Johnson M,Wright A,Zhou L,Wang SV

    更新日期:2019-09-01 00:00:00

  • Cardiac effects of ebastine and other antihistamines in humans.

    abstract::The electrocardiographic effects of ebastine and its active metabolite, carebastine, have been studied alone and in relevant drug-interaction studies in various patient populations. The overall cardiac tolerability of ebastine is excellent. In ebastine dose-ranging studies in adults and children, there were no meaning...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921001-00009

    authors: Moss AJ,Morganroth J

    更新日期:1999-01-01 00:00:00

  • Impact of electrocardiographic data quality on moxifloxacin response in thorough QT/QTc studies.

    abstract:BACKGROUND:Thorough QT studies are typically conducted for drugs with systemic bioavailability and include a positive control, typically moxifloxacin, with a well-described QTc effect. OBJECTIVE:This study tested two hypotheses: that (i) re-measuring the QT intervals based on electrocardiogram (ECG) pattern similarity...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0142-2

    authors: Johannesen L,Garnett C,Malik M

    更新日期:2014-03-01 00:00:00

  • Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.

    abstract::Since 2008, the direct-acting oral anticoagulants (DOACs) have expanded the therapeutic options of cardiovascular diseases with recognized clinical and epidemiological impact, such as non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE), and also in the preventive setting of orthopedic surgical pat...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0464-3

    authors: Raschi E,Bianchin M,Ageno W,De Ponti R,De Ponti F

    更新日期:2016-12-01 00:00:00

  • Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

    abstract::Regular treatment with both long- and short-acting beta 2-agonists results in tolerance to their bronchoprotective effects, although the relevance of this phenomenon in terms of long term asthma control remains unclear. However, there appears to be no appreciable difference between the 2 long-active beta 2-agonists, s...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199716050-00002

    authors: Lipworth BJ

    更新日期:1997-05-01 00:00:00

  • Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

    abstract::Pharmacovigilance science has traditionally been a discipline focussed on the postmarketing or post-authorisation period, with due attention directed towards pre-clinical safety data, clinical trials and adverse events. As the biological sciences have evolved, pharmacovigilance has slowly shifted toward earlier, proac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629080-00003

    authors: Hartford CG,Petchel KS,Mickail H,Perez-Gutthann S,McHale M,Grana JM,Marquez P

    更新日期:2006-01-01 00:00:00

  • A risk-benefit assessment of HIV protease inhibitors.

    abstract::The use of triple regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international guidelines. The widespread availabilit...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920040-00002

    authors: Moyle GJ,Gazzard BG

    更新日期:1999-04-01 00:00:00

  • Patient Reporting in the EU: Analysis of EudraVigilance Data.

    abstract:INTRODUCTION:New pharmacovigilance legislation was adopted in the EU in 2010 and became operational in July 2012. The legislation placed an obligation on all national competent authorities (NCAs) and marketing authorisation holders (MAHs) to record and report cases of suspected adverse drug reactions (ADRs) received fr...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0534-1

    authors: Banovac M,Candore G,Slattery J,Houÿez F,Haerry D,Genov G,Arlett P

    更新日期:2017-07-01 00:00:00

  • beta-blockers. Drug interactions of clinical significance.

    abstract::The clinician prescribing beta-blockers for his or her patients is faced with an often difficult situation. There are many beta-blockers, each with its own pharmacological profile. Patients are often taking multiple medications, thus increasing the risk of both anticipated and unexpected drug interactions. Reports of ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199513060-00005

    authors: Blaufarb I,Pfeifer TM,Frishman WH

    更新日期:1995-12-01 00:00:00

  • Discourse on safe drug use: symbolic logics and ethical aspects.

    abstract::Drug safety is not a matter for healthcare professionals alone. Patients are also involved, at three different levels: (i) in the behaviours patients adopt to reduce the adverse effects of the drugs; (ii) in regard to what some doctors say to their patients about drug risks; and (iii) in what the pharmaceutical indust...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11538320-000000000-00000

    authors: Fainzang S

    更新日期:2010-08-01 00:00:00

  • A Comparative View of Reported Adverse Effects of Statins in Social Media, Regulatory Data, Drug Information Databases and Systematic Reviews.

    abstract:INTRODUCTION:There are few studies assessing how data on adverse drug events from consumers on social media compare with other sources. AIM:The aim of this study was to assess the consistency of adverse event data of statin medications from social media as compared with other sources. METHODS:We collected data on the...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00998-1

    authors: Golder S,Smith K,O'Connor K,Gross R,Hennessy S,Gonzalez-Hernandez G

    更新日期:2021-02-01 00:00:00

  • Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

    abstract::Epilepsy is one of the most common neurological disorders. Even though existing antiepileptic drugs can render 80% of newly diagnosed patients seizure free, a significant number of patients have chronic intractable epilepsy causing disability with considerable socioeconomic implications. There is, therefore, a need fo...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411010-00005

    authors: Patsalos PN,Sander JW

    更新日期:1994-07-01 00:00:00

  • Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.

    abstract:BACKGROUND:Newly approved drugs, in comparison with older drugs, are more often prescribed to patients who have not responded satisfactorily to established related drugs or as first-line therapy to patients with a high baseline risk for adverse outcomes (i.e. channelling). However, these patients are less likely to ben...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200831020-00004

    authors: Layton D,Souverein PC,Heerdink ER,Shakir SA,Egberts AC

    更新日期:2008-01-01 00:00:00

  • Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

    abstract:INTRODUCTION:Non-steroidal anti-inflammatory drugs are associated with a dose and duration-dependent coronary risk. There is little information concerning analgesic-dose ibuprofen, among the most widely used drugs worldwide. OBJECTIVE:Our objective was to measure the risks of acute coronary syndrome (ACS) after dispen...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-0686-7

    authors: Duong M,Abouelfath A,Lassalle R,Droz C,Blin P,Moore N

    更新日期:2018-11-01 00:00:00

  • Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.

    abstract::In general, the selective estrogen receptor modulators (SERMs) currently indicated for the treatment and prevention of breast cancer, i.e. tamoxifen and toremifene, are fairly well tolerated. However, tamoxifen has been shown to induce hepatocellular carcinomas in rats, but not in humans, and can increase the risk of ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124140-00003

    authors: Curtis MG

    更新日期:2001-01-01 00:00:00

  • Erice Call for Change: Utilising Patient Experiences to Enhance the Quality and Safety of Healthcare.

    abstract::This 'Erice Call for Change' is a report from a group of experts, patients and patient representatives who met in Erice in September 2019 following previous similar meetings after the original Erice Declaration (1996). The aim of the meeting was to discuss the challenge of causal complexity and individual variation in...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00919-2

    authors: Rocca E,Anjum RL

    更新日期:2020-06-01 00:00:00

  • Performance of probabilistic method to detect duplicate individual case safety reports.

    abstract:BACKGROUND:Individual case reports of suspected harm from medicines are fundamental for signal detection in postmarketing surveillance. Their effective analysis requires reliable data and one challenge is report duplication. These are multiple unlinked records describing the same suspected adverse drug reaction (ADR) i...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0146-y

    authors: Tregunno PM,Fink DB,Fernandez-Fernandez C,Lázaro-Bengoa E,Norén GN

    更新日期:2014-04-01 00:00:00

  • Today's challenges in pharmacovigilance: what can we learn from epoetins?

    abstract::Highly publicized safety issues of medicinal products in recent years and the accompanying political pressure have forced both the US FDA and the European Medicines Agency (EMA) to implement stronger regulations concerning pharmacovigilance. These legislative changes demand more proactive risk management strategies of...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11586350-000000000-00000

    authors: Ebbers HC,Mantel-Teeuwisse AK,Moors EH,Schellekens H,Leufkens HG

    更新日期:2011-04-01 00:00:00

  • Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

    abstract:BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11598050-000000000-00000

    authors: Manzoli L,De Vito C,Marzuillo C,Boccia A,Villari P

    更新日期:2012-03-01 00:00:00

  • Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?

    abstract::Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over the past 6 years has now clarified the contribution of specific ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200528120-00002

    authors: Nolan D

    更新日期:2005-01-01 00:00:00

  • Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.

    abstract::Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. The overall number of boxed warnings has grown in recent years as the US Food and Drug Administration (FDA) has approved more drugs on the basis of limited pre-marketing information and as n...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0419-8

    authors: Yeh JS,Sarpatwari A,Kesselheim AS

    更新日期:2016-08-01 00:00:00

  • Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

    abstract::The biologics have revolutionized the treatment of rheumatoid arthritis (RA). However, there are still patients that are difficult to control and a cure is still not achievable. Tofacitinib, a Janus kinase (JAK) inhibitor is an orally available, new-in-class, disease-modifying anti-rheumatic drug with similar efficacy...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0430-0

    authors: Yamaoka K

    更新日期:2016-09-01 00:00:00

  • Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries.

    abstract:BACKGROUND:Acute liver failure is idiopathic and drug-related in, respectively, around 50 and 15 % of children. Population-based, epidemiologic data about the pattern of disease manifestation and incidence of less severe acute liver injury, either idiopathic or potentially drug-attributed are limited in children and ad...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0045-7

    authors: Ferrajolo C,Verhamme KM,Trifirò G,'t Jong GW,Giaquinto C,Picelli G,Oteri A,de Bie S,Valkhoff VE,Schuemie MJ,Mazzaglia G,Cricelli C,Rossi F,Capuano A,Sturkenboom MC

    更新日期:2013-10-01 00:00:00